In-Depth Interview with Chairman Tse-Wen Chang: Leading T-E Meds in Advancing ADC Technology
T-E Meds has distinguished itself from a highly competitive pool of global nominees and has been selected as one of […]
Reported
News
T-E Meds Shortlisted for World ADC Awards – Best New Drug Developer
T-E Pharma announced that its subsidiary, T-E Meds, Inc., has been shortlisted for the prestigious “Best New Drug Developer” category
Meeing
Join our presentation at the Asia BIO Innovation Summit 2025
We’re proud to share that Dr. Cédric Grauffel, Manager of T-E Drug Design at T-E Meds, will be presenting at
R&D Progress
TE-1146 drug development was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan
“The development of the novel drug, TE-1146, the CD38 specific antibody drug conjugate (ADC)” was selected as a significant case
Meeing
Join our presentation at the BIO Asia-Taiwan 2025 Conference
We’re excited to announce that Dr. Art Hsing-Mao Chu, CEO of T-E Meds, an affiliate company of T-E PHARMA, will
R&D Progress
Immunwork Announces Positive Phase I Top-Line Data for TE-8214, a Long-Acting Octreotide, Demonstrating Favorable Safety, Tolerability, and Potent IGF-1 Suppression
• Pioneering Patient Experience: TE-8214, a highly water-soluble aqueous solution, enables pain-free subcutaneous injection with a thin 30G needle, eliminating injection
News
T-E Meds and Asymchem Join Forces to Drive Innovation in Drug Conjugates and Explore the Future of Targeted Therapeutics
On June 24, 2025, T-E Meds and Asymchem Laboratories successfully signed a strategic cooperation agreement. This partnership marks the beginning
Meeing
Join our presentation at the World ADC Asia 2025 Conference
We’re proud to share that Dr. Art Hsing-Mao Chu, CEO of T-E Meds, will be presenting at the 4th World
Meeing
【Reported by Taiwan Global Bio Monthly】The President, Dr. Tse-Wen Chang was invited as a keynote speaker at Biologics World Taiwan 2025
Website link: https://news.gbimonthly.com/tw/article/show.php?num=75729&page=1